The COMT Val158 met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers

BMC Neuroscience

Volumn 10, Issue , 2009, Pages 125-

  Martínez, Manuel F ^a   Martín, Xabier E ^b   Alcelay, Luís G ^c   Flores, Jessica C ^a   Valiente, Juan M U ^d   Juanbeltz, Begoña I ^e   Beldarraín, María Ángeles Gómez ^f   López, Josefa Moraza ^c   Gonzalez Fernández, María Carmen ^b   Salazar, Ana Molano ^a   Gandarias, Rocio Bereincua ^a   Borda, Sandra Inglés ^c   Marqués, Nuria Ortiz ^d   Amillano, Miryam Barandiarán ^e   Zabaleta, María Carrasco ^f   De Pancorbo, Marian M ^b  

^a HOSPITAL DE CRUCES   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c HOSPITAL TXAGORRITXU   (Spain)

^d HOSPITAL DE BASURTO   (Spain)

^e HOSPITAL DONOSTIA   (Spain)

^f HOSPITAL DE GALDAKAO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; CATECHOL METHYLTRANSFERASE; METHIONINE; VALINE;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; APOLIPOPROTEIN E4; CATECHOL O-METHYLTRANSFERASE; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; ODDS RATIO; PATIENT SELECTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SEX FACTORS;

EID: 70449642520     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-10-125     Document Type: Article

References (42)

1. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261(5123):921-923. 10.1126/science.8346443, 8346443.
2. Shield AJ, Thomae BA, Eckloff BW, Wieben ED, Weinshilboum RM. Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol Psychiatry 2004, 9(2):151-160. 10.1038/sj.mp.4001386, 14966473.
3. Nock NL, Cicek MS, Li L, Liu X, Rybicki BA, Moreira A, Plummer SJ, Casey G, Witte JS. Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 2006, 27(9):1842-1848. 10.1093/carcin/bgl022, 16569655.
4. Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Finch CE. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. J Neurosci 1998, 18(9):3180-3185.
5. Wen Y, Yang S, Liu R, Perez E, Yi KD, Koulen P, Simpkins JW. Estrogen attenuates nuclear factor-kappa B activation induced by transient cerebral ischemia. Brain Res 2004, 1008(2):147-154. 10.1016/j.brainres.2004.02.019, 15145751.
6. Cordey M, Gundimeda U, Gopalakrishna R, Pike CJ. Estrogen activates protein kinase C in neurons: role in neuroprotection. J Neurochem 2003, 84(6):1340-1348. 10.1046/j.1471-4159.2003.01631.x, 12614334.
7. Gandy S. Estrogen and neurodegeneration. Neurochem Res 2003, 28(7):1003-1008. 10.1023/A:1023246921127, 12737524.
8. Baldereschi M, Di Carlo A, Lepore V, Bracco L, Maggi S, Grigoletto F, Scarlato G, Amaducci L. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology 1998, 50(4):996-1002.
9. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle DD, Metter E. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997, 48(6):1517-1521.
10. Wang PN, Liu HC, Liu TY, Chu A, Hong CJ, Lin KN, Chi CW. Estrogen-metabolizing gene COMT polymorphism synergistic APOE epsilon4 allele increases the risk of Alzheimer disease. Dement Geriatr Cogn Disord 2005, 19(2-3):120-125. 10.1159/000082663, 15591802.
11. Borroni B, Grassi M, Costanzi C, Zanetti M, Archetti S, Franzoni S, Caimi L, Padovani A. Haplotypes in cathechol-O-methyltransferase gene confer increased risk for psychosis in Alzheimer disease. Neurobiol Aging 2007, 28(8):1231-1238. 10.1016/j.neurobiolaging.2006.05.027, 16837108.
12. Sweet RA, Devlin B, Pollock BG, Sukonick DL, Kastango KB, Bacanu SA, Chowdari KV, DeKosky ST, Ferrell RE. Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease. Mol Psychiatry 2005, 10(11):1026-1036. 10.1038/sj.mp.4001709, 16027741.
13. Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov 2003, 2(8):646-653. 10.1038/nrd1155, 12904814.
14. American Psychiatric Association DSM-IV. Diagnostic and Statistical manual of mental disorders. 1994, American Psychiatric Association, Washington.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34(7):939-944.
16. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004, 256(3):240-246. 10.1111/j.1365-2796.2004.01380.x, 15324367.
17. Wilton S, Lim L. Rapid identification of ApoE alleles by multiple-single-strand conformation polymorphism (SSCP) analysis. Trends Genet 1995, 11(9):341. 10.1016/S0168-9525(00)89102-7, 7482784.
18. Alvarez-Alvarez M, Galdos L, Fernandez-Martinez M, Gomez-Busto F, Garcia-Centeno V, Arias-Arias C, Sanchez-Salazar C, Rodriguez-Martinez AB, Zarranz JJ, de Pancorbo MM. 5-Hydroxytryptamine 6 receptor (5-HT(6)) receptor and apolipoprotein E (ApoE) polymorphisms in patients with Alzheimer's disease in the Basque Country. Neurosci Lett 2003, 339(1):85-87. 10.1016/S0304-3940(02)01425-8, 12618306.
19. Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992, 48(2):361-372. 10.2307/2532296, 1637966.
20. Forero DA, Benitez B, Arboleda G, Yunis JJ, Pardo R, Arboleda H. Analysis of functional polymorphisms in three synaptic plasticity-related genes (BDNF, COMT AND UCHL1) in Alzheimer's disease in Colombia. Neurosci Res 2006, 55(3):334-341. 10.1016/j.neures.2006.04.006, 16698101.
21. Barabash A, Marcos A, Ancin I, Vazquez-Alvarez B, de Ugarte C, Gil P, Fernandez C, Encinas M, Lopez-Ibor JJ, Cabranes JA. APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 2009, 30(8):1254-1264. 10.1016/j.neurobiolaging.2007.11.003, 18078695.
22. Modrego PJ. Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Current Alzheimer research 2006, 3(2):161-170. 10.2174/156720506776383103, 16611017.
23. Petersen RC, Waring SC, Smith GE, Tangalos EG, Thibodeau SN. Predictive value of APOE genotyping in incipient Alzheimer's disease. Ann N Y Acad Sci 1996, 802:58-69. 10.1111/j.1749-6632.1996.tb32599.x, 8993485.
24. Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, Scarmeas N, Braun I, Stern Y, Mayeux R. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol 2005, 62(6):975-980. 10.1001/archneur.62.6.975, 15956169.
25. White F, Nicoll JA, Horsburgh K. Alterations in ApoE and ApoJ in relation to degeneration and regeneration in a mouse model of entorhinal cortex lesion. Exp Neurol 2001, 169(2):307-318. 10.1006/exnr.2001.7655, 11358444.
26. Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 2000, 54(11):2072-2077.
27. Mortensen EL, Hogh P. A gender difference in the association between APOE genotype and age-related cognitive decline. Neurology 2001, 57(1):89-95.
28. Yaffe K, Haan M, Byers A, Tangen C, Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 2000, 54(10):1949-1954.
29. Worda C, Sator MO, Schneeberger C, Jantschev T, Ferlitsch K, Huber JC. Influence of the catechol-O-methyltransferase (COMT) codon 158 polymorphism on estrogen levels in women. Hum Reprod 2003, 18(2):262-266. 10.1093/humrep/deg059, 12571159.
30. Ball P, Knuppen R. Catecholoestrogens (2-and 4-hydroxyoestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance. Acta Endocrinol Suppl (Copenh) 1980, 232:1-127.
31. Kaytor MD, Orr HT. The GSK3 beta signaling cascade and neurodegenerative disease. Curr Opin Neurobiol 2002, 12(3):275-278. 10.1016/S0959-4388(02)00320-3, 12049933.
32. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annual review of neuroscience 2001, 24:1121-1159. 10.1146/annurev.neuro.24.1.1121, 11520930.
33. Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 2007, 25(1):59-68. 10.1111/j.1460-9568.2006.05226.x, 17241267.
34. Yagi E, Barrett JC, Tsutsui T. The ability of four catechol estrogens of 17beta-estradiol and estrone to induce DNA adducts in Syrian hamster embryo fibroblasts. Carcinogenesis 2001, 22(9):1505-1510. 10.1093/carcin/22.9.1505, 11532873.
35. Lovell MA, Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res 2007, 35(22):7497-7504. 10.1093/nar/gkm821, 2190704, 17947327.
36. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005, 64(7):1152-1156.
37. Lane R, He Y, Morris C, Leverenz JB, Emre M, Ballard C. BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord 2009, 24(3):392-400. 10.1002/mds.22357, 19006190.
38. Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, Darreh-Shori T, Soininen H, Pirttila T, Farlow MR. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenetics and genomics 2008, 18(4):289-298. 10.1097/FPC.0b013e3282f63f29, 18334913.
39. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. The pharmacogenomics journal 2006, 6(4):246-254.
40. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43(3):321-332. 10.1016/j.neuron.2004.07.003, 15294141.
41. Luine VN, McEwen BS. Sex differences in cholinergic enzymes of diagonal band nuclei in the rat preoptic area. Neuroendocrinology 1983, 36(6):475-482. 10.1159/000123501, 6877524.
42. Luine VN, Renner KJ, Heady S, Jones KJ. Age and sex-dependent decreases in ChAT in basal forebrain nuclei. Neurobiol Aging 1986, 7(3):193-198. 10.1016/0197-4580(86)90042-4, 3724953.